Hereditary Angioedema Treatment Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032
CHAPTER 1. Industry Overview of Hereditary Angioedema Treatment Market
1.1. Definition and Scope
1.1.1. Definition of Hereditary Angioedema Treatment
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Hereditary Angioedema Treatment Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Hereditary Angioedema Treatment Market By Drug Class
1.2.3. Hereditary Angioedema Treatment Market By Treatment Type
1.2.4. Hereditary Angioedema Treatment Market By Route of Administration
1.2.5. Hereditary Angioedema Treatment Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Hereditary Angioedema Treatment Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Hereditary Angioedema Treatment Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Price Trend of Key Raw Materials
3.8.2. Raw Material Suppliers
3.8.3. Proportion of Manufacturing Cost Structure
3.8.3.1. Raw Material
3.8.3.2. Labor Cost
3.8.3.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2022
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Route of Administration and Establish Date of Major Manufacturers in 2022
4.2. R&D Status of Major Manufacturers in 2022
CHAPTER 5. Hereditary Angioedema Treatment Market By Drug Class
5.1. Introduction
5.2. Hereditary Angioedema Treatment Revenue By Drug Class
5.2.1. Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast, By Drug Class, 2020-2032
5.2.2. C1-Esterase Inhibitor
5.2.2.1. C1- Esterase Inhibitor Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.3. Bradykinin B2 Receptor Antagonist
5.2.3.1. Bradykinin B2 Receptor Antagonist Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.4. Kallikrein Inhibitor
5.2.4.1. Kallikrein Inhibitor Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.5. Others
5.2.5.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 6. Hereditary Angioedema Treatment Market By Treatment Type
6.1. Introduction
6.2. Hereditary Angioedema Treatment Revenue By Treatment Type
6.2.1. Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast, By Treatment Type, 2020-2032
6.2.2. Prophylaxis
6.2.2.1. Prophylaxis Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.3. On-demand
6.2.3.1. On-demand Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 7. Hereditary Angioedema Treatment Market By Route of Administration
7.1. Introduction
7.2. Hereditary Angioedema Treatment Revenue By Route of Administration
7.2.1. Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast, By Route of Administration, 2020-2032
7.2.2. Intravenous
7.2.2.1. Intravenous Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.3. Subcutaneous
7.2.3.1. Subcutaneous Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.4. Oral
7.2.4.1. Oral Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 8. North America Hereditary Angioedema Treatment Market By Country
8.1. North America Hereditary Angioedema Treatment Market Overview
8.2. U.S.
8.2.1. U.S. Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
8.2.2. U.S. Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2020-2032
8.2.3. U.S. Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
8.3. Canada
8.3.1. Canada Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
8.3.2. Canada Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2020-2032
8.3.3. Canada Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
8.4. North America PEST Analysis
CHAPTER 9. Europe Hereditary Angioedema Treatment Market By Country
9.1. Europe Hereditary Angioedema Treatment Market Overview
9.2. U.K.
9.2.1. U.K. Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.2.2. U.K. Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2020-2032
9.2.3. U.K. Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
9.3. Germany
9.3.1. Germany Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.3.2. Germany Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2020-2032
9.3.3. Germany Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
9.4. France
9.4.1. France Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.4.2. France Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2020-2032
9.4.3. France Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
9.5. Spain
9.5.1. Spain Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.5.2. Spain Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2020-2032
9.5.3. Spain Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
9.6. Rest of Europe
9.6.1. Rest of Europe Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.6.2. Rest of Europe Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2020-2032
9.6.3. Rest of Europe Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Hereditary Angioedema Treatment Market By Country
10.1. Asia Pacific Hereditary Angioedema Treatment Market Overview
10.2. China
10.2.1. China Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.2.2. China Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2020-2032
10.2.3. China Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
10.3. Japan
10.3.1. Japan Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.3.2. Japan Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2020-2032
10.3.3. Japan Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
10.4. India
10.4.1. India Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.4.2. India Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2020-2032
10.4.3. India Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
10.5. Australia
10.5.1. Australia Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.5.2. Australia Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2020-2032
10.5.3. Australia Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
10.6. South Korea
10.6.1. South Korea Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.6.2. South Korea Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2020-2032
10.6.3. South Korea Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By End-User, 2020-2032
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.7.2. Rest of Asia-Pacific Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2020-2032
10.7.3. Rest of Asia-Pacific Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
CHAPTER 11. Latin America Hereditary Angioedema Treatment Market By Country
11.1. Latin America Hereditary Angioedema Treatment Market Overview
11.2. Brazil
11.2.1. Brazil Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
11.2.2. Brazil Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2020-2032
11.2.3. Brazil Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
11.3. Mexico
11.3.1. Mexico Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
11.3.2. Mexico Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2020-2032
11.3.3. Mexico Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
11.4. Rest of Latin America
11.4.1. Rest of Latin America Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
11.4.2. Rest of Latin America Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2020-2032
11.4.3. Rest of Latin America Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
11.5. Latin America PEST Analysis
CHAPTER 12. Middle East & Africa Hereditary Angioedema Treatment Market By Country
12.1. Middle East & Africa Hereditary Angioedema Treatment Market Overview
12.2. GCC
12.2.1. GCC Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
12.2.2. GCC Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2020-2032
12.2.3. GCC Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
12.3. South Africa
12.3.1. South Africa Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
12.3.2. South Africa Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2020-2032
12.3.3. South Africa Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
12.4.2. Rest of Middle East & Africa Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2020-2032
12.4.3. Rest of Middle East & Africa Hereditary Angioedema Treatment Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
12.5. Middle East & Africa PEST Analysis
CHAPTER 13. Player Analysis Of Hereditary Angioedema Treatment Market
13.1. Hereditary Angioedema Treatment Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Hereditary Angioedema Treatment Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 14. Company Profile
14.1. BioMarin Pharmaceutical Inc.
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (USD Billion), 2022
14.1.3.2. BioMarin Pharmaceutical Inc. 2022 Hereditary Angioedema Treatment Business Regional Distribution
14.1.4. Product /Service and Specification
14.1.5. Recent Developments & Business Strategy
14.2. Dyax Corp.
14.3. Shire (now part of Takeda)
14.4. Salix Pharmaceuticals
14.5. Pharming Group NV
14.6. Pharvaris N.V.
14.7. Arrowhead Pharmaceuticals
14.8. Ionis Pharmaceuticals
14.9. CSL Limited
14.10. Attune Pharmaceuticals
14.11. Adverum Biotechnologies, Inc.
14.12. KalVista Pharmaceuticals, Inc.
Frequently Asked Questions
What was the size of the hereditary angioedema treatment market?
The size of hereditary angioedema treatment market was USD 2.9 billion in 2022.
What is the CAGR of the hereditary angioedema treatment market from 2023 to 2032?
The CAGR of hereditary angioedema treatment is 8.9% during the analysis period of 2023 to 2032.
Which are the key players in the hereditary angioedema treatment market?
The key players operating in the global market are BioMarin Pharmaceutical Inc., Dyax Corp., Shire (now part of Takeda), Salix Pharmaceuticals, Pharming Group NV, Pharvaris N.V., Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, CSL Limited, Attune Pharmaceuticals, Adverum Biotechnologies, Inc., and KalVista Pharmaceuticals, Inc.
Which region dominated the global hereditary angioedema treatment market share?
North America held the dominating position in hereditary angioedema treatment industry during the analysis period of 2023 to 2032.
Which region registered fastest CAGR from 2023 to 2032?
Asia-Pacific region exhibited fastest growing CAGR for market of hereditary angioedema treatment during the analysis period of 2023 to 2032.
What are the current trends and dynamics in the global hereditary angioedema treatment industry?
The current trends and dynamics in the hereditary angioedema treatment industry include increasing awareness and diagnosis of HAE, and advancements in HAE treatment options, and growing research in genetic therapies.
Which drug class held the maximum share in 2022?
The C1-esterase inhibitor drug class held the maximum share of the hereditary angioedema treatment industry.
Select Licence Type
Connect with our sales team
Why Acumen Research And Consulting
100%
Customer Satisfaction
24x7
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
